Study of clinical effects and antibacterial activity of grepafloxacin

DOI 2 References

Bibliographic Information

Other Title
  • Grepafloxacinの抗菌力ならびに臨床的検討

Search this article

Abstract

The antimicrobial activity and clinical effects of a new quinolone antimicrobial drug, grepafloxacin (GPFX), were investigated.<BR>Minimum inhibitory concentrations (MICs) of the drug against 209 strains of 7 clinically isolated species were determined to examine the antibacterial activity of the drug. GPFX showed minimum 50% inhibitory concentration (MIC50) levels of 0.09μg/ml, 0.09μg/ml, 0.09μg/ml, 1.56μg/ml, 0.19μg/ml, 0.09μg/ml, and 0.78μg/ml against Staphylococcus aureus, Escherichia coli, Klebsiella pneumaniae, Serratia marcescens, Proteus mirabilis, Morganella morganii, and Pseudomonas aeruginosa, respectively. Minimum 90% inhibitory concentration (MIC90) levels were 0.09μg/ml against E. coli, 0.19μg/ml against K. pneumoniae, 0.19μg/ml against M. morganii, and 0.39μg/ml against P. mirabilis. Thus, GPFX exerted good antibacterial activity against these four species.<BR>GPFX was also administered to 13 patients with respiratory infectious diseases (8 with bronchitis, 2 with acute aggravation of chronic bronchitis, and 3 with secondary airway infection) at a daily dose of 100-300mg for 7-14 days, and the clinical effects were investigated. The drug was effective in 11, slightly effective in 1, and unknown in 1 because the patient did not visit the hospital after administration. None of the patients had side effects or abnormalities on clinical laboratory tests, excluding the patient who was lost to follow-up.

Journal

References(2)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top